CHARLES COLE: Open Payments
NPI 1316021751 · MEADVILLE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$896 in 44 payments from 16 companies in 2025. Trend: 2023 $878 · 2024 $797 · 2025 $896
Food & beverage: $896
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $240 |
| Otsuka America Pharmaceutical, Inc. | 5 | $102 |
| Novartis Pharmaceuticals Corporation | 3 | $69 |
| Amgen Inc. | 3 | $62 |
| Lundbeck LLC | 3 | $61 |
| Lilly USA, LLC | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| PFIZER INC. | 3 | $46 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $40 |
Products named: REXULTI, LUMIGAN, VRAYLAR, OTEZLA, MOUNJARO, TRINTELLIX, CAPLYTA, XIFAXAN.
Industry payments across PA — which companies pay providers there.
